Clinical Question:
Your hospital pharmacy director wants to initiate a proton pump therapeutic interchange program. Which of the proton pump inhibitors can be extemporaneously compounded into a solution or suspension for nasogastric (NG) administration?
Major Concepts?
What are the most important concepts contained within this question?